141 related articles for article (PubMed ID: 30911698)
1. A unique case of chronic myeloid leukemia presenting as monocular vision loss with unilateral retinopathy.
Seraly MP; Gupta SK; Mehmi I; Veltri L; Ghorayeb GR
Am J Ophthalmol Case Rep; 2019 Jun; 14():67-69. PubMed ID: 30911698
[TBL] [Abstract][Full Text] [Related]
2. Massive retinal infiltrates as the presenting sign of chronic myeloid leukemia: Clinical and imaging features of leukemic retinopathy.
Szeto SK; Mohamed S; Tsang CW; Chan CK
Eur J Ophthalmol; 2023 Jan; 33(1):NP55-NP63. PubMed ID: 34595942
[TBL] [Abstract][Full Text] [Related]
3. EUTOS CML prognostic scoring system predicts ELN-based 'event-free survival' better than Euro/Hasford and Sokal systems in CML patients receiving front-line imatinib mesylate.
Uz B; Buyukasik Y; Atay H; Kelkitli E; Turgut M; Bektas O; Eliacik E; Isik A; Aksu S; Goker H; Sayinalp N; Ozcebe OI; Haznedaroglu IC
Hematology; 2013 Sep; 18(5):247-52. PubMed ID: 23540886
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the utility and applicability of the Sokal, Hasford, and EUTOS scores in a population of Chinese patients with chronic-phase chronic myeloid leukemia undergoing imatinib therapy.
Xia L; Qian W; Yang M; Li Q; Liu F; Xie Y
Onco Targets Ther; 2015; 8():2485-92. PubMed ID: 26392775
[TBL] [Abstract][Full Text] [Related]
5. [Clinical significance of Sokal, Hasford and EUTOS prognostic scoring systems in chronic myeloid leukemia].
Feng G; Wang J; Jiang Y; Li Y; Ding M; Wang N; Wang X
Zhonghua Xue Ye Xue Za Zhi; 2014 Aug; 35(8):743-6. PubMed ID: 25152126
[TBL] [Abstract][Full Text] [Related]
6. Bilateral vision loss as initial presentation of chronic myeloid leukemia in a young adult: A case report and review of the literature.
Brown NJ; Kaya EA; Haymore JG; Gioia LV
Am J Ophthalmol Case Rep; 2022 Jun; 26():101579. PubMed ID: 35602313
[TBL] [Abstract][Full Text] [Related]
7. A Case of Chronic Myeloid Leukemia Presenting as Bilateral Retinopathy.
Kandambeth V; Shinde P; Daigavane S
Cureus; 2022 Nov; 14(11):e31718. PubMed ID: 36569729
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of Three Prognostic Scoring Systems in Predicting the Response and Outcome in Pediatric Chronic Myeloid Leukemia Chronic Phase on Frontline Imatinib.
Ganta RR; Nasaka S; Linga VG; Gundeti S; Maddali LS; Digumarti RR
Indian J Med Paediatr Oncol; 2017; 38(3):282-286. PubMed ID: 29200674
[TBL] [Abstract][Full Text] [Related]
9. A comparative study of Hasford score and Sokal index in prognostication of the novo chronic myeloid leukemia patients and a search for new prognostic markers.
Sinha SK; Sinha S; Mandal PK; Bhattacharyya NK; Pandey A; Gupta P
Indian J Pathol Microbiol; 2013; 56(3):216-20. PubMed ID: 24152497
[TBL] [Abstract][Full Text] [Related]
10. Pars plana lensectomy, pars plana vitrectomy, and silicone oil tamponade as initial management of cataract and combined traction/rhegmatogenous retinal detachment involving the macula associated with severe proliferative diabetic retinopathy.
Douglas MJ; Scott IU; Flynn HW
Ophthalmic Surg Lasers Imaging; 2003; 34(4):270-8. PubMed ID: 12875454
[TBL] [Abstract][Full Text] [Related]
11. Early BCR-ABL1 Reduction Is Predictive of Better Event-free Survival in Patients With Newly Diagnosed Chronic Myeloid Leukemia Treated With Any Tyrosine Kinase Inhibitor.
Fava C; Rege-Cambrin G; Dogliotti I; Gottardi E; Berchialla P; Di Gioacchino B; Crasto F; Lorenzatti R; Volpengo A; Daraio F; Fantino C; Saglio G
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S96-S100. PubMed ID: 27131622
[TBL] [Abstract][Full Text] [Related]
12. Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR.
Ross DM; Branford S; Seymour JF; Schwarer AP; Arthur C; Bartley PA; Slader C; Field C; Dang P; Filshie RJ; Mills AK; Grigg AP; Melo JV; Hughes TP
Leukemia; 2010 Oct; 24(10):1719-24. PubMed ID: 20811403
[TBL] [Abstract][Full Text] [Related]
13. Ocular involvement-An unusual initial presentation of chronic myeloid leukemia: A case report.
Khurana M; Singh A; Pal H; Gupta AK; Kumar B
J Family Med Prim Care; 2023 Jul; 12(7):1460-1463. PubMed ID: 37649755
[TBL] [Abstract][Full Text] [Related]
14. A rare e13a3 (b2a3) BCR-ABL1 fusion transcript with normal karyotype in chronic myeloid leukemia: The challenges in diagnosis and monitoring minimal residual disease (MRD).
Duan MH; Li H; Cai H
Leuk Res; 2017 Aug; 59():8-11. PubMed ID: 28527402
[TBL] [Abstract][Full Text] [Related]
15. Finding the right BCR-ABL1 tyrosine kinase inhibitor: a case report of successful treatment of a patient with chronic myeloid leukemia and a V299L mutation using nilotinib.
Elnair R; Galal A
BMC Cancer; 2018 Nov; 18(1):1097. PubMed ID: 30419862
[TBL] [Abstract][Full Text] [Related]
16. Cytogenetic, fluorescence in situ hybridization, and genomic array characterization of chronic myeloid leukemia with cryptic BCR-ABL1 fusions.
Shao L; Miller S; Keller-Ramey J; Zhang Y; Roulston D
Cancer Genet; 2015; 208(7-8):396-403. PubMed ID: 26186983
[TBL] [Abstract][Full Text] [Related]
17. Unilateral Subhyaloid Hemorrhage as a Presenting Sign of Chronic Myeloid Leukemia.
Almater AI; Alhadlaq GS; Alromaih AZ
Am J Case Rep; 2022 Apr; 23():e936266. PubMed ID: 35484832
[TBL] [Abstract][Full Text] [Related]
18. Dasatinib rapidly induces deep molecular response in chronic-phase chronic myeloid leukemia patients who achieved major molecular response with detectable levels of BCR-ABL1 transcripts by imatinib therapy.
Shiseki M; Yoshida C; Takezako N; Ohwada A; Kumagai T; Nishiwaki K; Horikoshi A; Fukuda T; Takano H; Kouzai Y; Tanaka J; Morita S; Sakamoto J; Sakamaki H; Inokuchi K
Int J Clin Oncol; 2017 Oct; 22(5):972-979. PubMed ID: 28550414
[TBL] [Abstract][Full Text] [Related]
19. Patan hospital experience in treating philadelphia chromosome/BCR-ABL1 positive chronic myeloid leukemia patients with gleevec (imatinib mesylate); the first generation specific tyrosine kinase inhibitor.
Kayastha GK; Gurung P; Acharya PK; Paudyal BP; Hayes B; Zimmerman M; Karki A; Mansfield AS
BMC Blood Disord; 2010 Dec; 10():8. PubMed ID: 21138592
[TBL] [Abstract][Full Text] [Related]
20. miR-96 acts as a tumor suppressor via targeting the BCR-ABL1 oncogene in chronic myeloid leukemia blastic transformation.
Huang T; Fu Y; Wang S; Xu M; Yin X; Zhou M; Wang X; Chen C
Biomed Pharmacother; 2019 Nov; 119():109413. PubMed ID: 31518872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
